Epigenetic regulation of the cell type-specific gene 14-3-3σ

Neoplasia

Volumn 7, Issue 9, 2005, Pages 799-808

  Oshiro, Marc M ^a   Futscher, Bernard W ^a   Lisberg, Aaron ^a   Wozniak, Ryan J ^a   Klimecki, Walter T ^b   Domann, Frederick E ^c   Cress, Anne E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

14 3 3 ; Chromatin; Histone; Histone acetylation; Methylation

Indexed keywords

HISTONE H3; LYSINE; PROTEIN 14 3 3; PROTEIN P53; EXONUCLEASE; HISTONE; SFN PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER GENETICS; CELL TYPE; CHROMATIN STRUCTURE; CPG ISLAND; GENE EXPRESSION; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROSTATE EPITHELIUM; ACETYLATION; CELL DIFFERENTIATION; CHROMATIN; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HISTONE CODE; METABOLISM; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ACETYLATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMATIN; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EXONUCLEASES; GENE EXPRESSION REGULATION; HISTONE CODE; HISTONES; HUMANS; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33644875123     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05274     Document Type: Article

References (59)

1. Li E, Bestor TH, and Jaenisch R (1992). Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915 - 926.
2. Gardiner-Garden M and Frommer M (1987). CpG islands in vertebrate genomes. J Mol Biol 196, 261 - 282.
3. Takai D and Jones PA (2003). The CpG island searcher: a new WWW resource. In Silico Biol 3, 235 - 240.
4. Ehrlich M (2002). DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400 - 5413.
5. Feinberg AP and Tycko B (2004). The history of cancer epigenetics. Nat Rev Cancer 4, 143 - 153.
6. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, and Domann FE (2002). Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31, 175 - 179.
7. Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ, and Nelkin BD (1986). DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 46, 2917 - 2922.
8. Feinberg AP and Vogelstein B (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89 - 92.
9. Herman JG and Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042 - 2054.
10. Beard C, Li E, and Jaenisch R (1995). Loss of methylation activates Xist in somatic but not in embryonic cells. Genes Dev 9, 2325 - 2334.
11. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, and Feinberg AP (2002). Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62, 6442 - 6446.
12. Fitzgerald M, Oshiro M, Holtan N, Krager K, Cullen JJ, Futscher BW, and Domann FE (2003). Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5, 427 - 436.
13. Li E, Beard C, and Jaenisch R (1993). Role for DNA methylation in genomic imprinting. Nature 366, 362 - 365.
14. Mohandas T, Sparkes RS, and Shapiro LJ (1981). Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 211, 393 - 396.
15. Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, Higuchi T, Tomisawa Y, Sato N, Endo S, et al. (2004). Disruption of cell-type - specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene gene 23, 1117 - 1124.
16. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, and Feinberg AP (1993). Relaxation of imprinted genes in human cancer. Nature 362, 747 - 749.
17. Sugimoto S, Maass N, Takimoto Y, Sato K, Minei S, Zhang M, Hoshikawa Y, Junemann KP, Jonat W, and Nagasaki K (2004). Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett 203, 209 - 215.
18. Yatabe Y, Mitsudomi T, and Takahashi T (2004). Maspin expression in normal lung and non -small-cell lung cancers: cellular property - associated expression under the control of promoter DNA methylation. Oncogene 23, 4041 - 4049.
19. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, and Tycko B (1993). Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. Am J Hum Genet 53, 113 - 124.
20. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, and Mandel JL (1991). Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252, 1097 - 1102.
21. Qu GZ, Grundy PE, Narayan A, and Ehrlich M (1999). Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes methylation 1 and 16. Cancer Genet Cytogenet 109, 34 - 39.
22. Robertson KD and Wolffe AP (2000). DNA methylation in health and disease. Nat Rev Genet 1, 11 - 19.
23. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, and Viegas-Pequignot E (1999). Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402, 187 - 191.
24. Greger V, Passarge E, Hopping W, Messmer E, and Horsthemke B (1989). Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83, 155 - 158.
25. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, and Dryja TP (1991). Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48, 880 - 888.
26. Esteller M, Corn PG, Baylin SB, and Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res 61, 3225 - 3229.
27. Widschwendter M and Jones PA (2002). DNA methylation and breast carcinogenesis. Oncogene 21, 5462 - 5482.
28. Chen H, Toyooka S, Gazdar AF, and Hsieh JT (2003). Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 278, 3121 - 3130.
29. Domann FE, Rice JC, Hendrix MJ, and Futscher BW (2000). Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85, 805 - 810.
30. Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, and Futscher BW (2003). Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22, 3624 - 3634.
31. Rice JC and Allis CD (2001). Code of silence. Nature 414, 258 - 261.
32. Rice JC and Futscher BW (2000). Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res 28, 3233 - 3239.
33. Yan L, Yang X, and Davidson NE (2001). Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 6, 183 - 192.
34. Lachner M and Jenuwein T (2002). The many faces of histone lysine methylation. Curr Opin Cell Biol 14, 286 - 298.
35. Prasad GL, Valverius EM, McDuffie E, and Cooper HL (1992). Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3, 507 - 513.
36. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, and Vogelstein B (1997). 14-3-3 Sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3 - 11.
37. Chan TA, Hermeking H, Lengauer C, Kinzler KW, and Vogelstein B (1999). 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616 - 620.
38. 1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell 5, 257 - 271.
39. Hermeking H (2003). The 14-3-3 cancer connection. Nat Rev Cancer 3, 931 - 943.
40. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, et al. (2000). High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97, 6049 - 6054.
41. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, et al. (2004). Loss of 14-3-3 sigma in prostate cancer and its precursors. Clin Cancer Res 10, 3064 - 3068.
42. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al. (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19, 5298 - 5302.
43. Lodygin D, Yazdi AS, Sander CA, Herzinger T, and Hermeking H (2003). Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22, 5519 - 5524.
44. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, and Takahashi T (2002). Frequent and histological type - specific inactivation of 14-3-3 sigma in human lung cancers. Oncogene 21, 2418 - 2424.
45. Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, Horie-Inoue K, Sasano H, Kitamura T, Ouchi Y, et al. (2004). 14-3-3 Sigma is down-regulated in human prostate cancer. Biochem Biophys Res Commun 319, 795 - 800.
46. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, and Sukumar S (2001). Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20, 3348 - 3353.
47. Huang Y and Domann FE (1999). Transcription factor AP-2 mRNA and DNA binding activity are constitutively expressed in SV40-immortalized but not normal human lung fibroblasts. Arch Biochem Biophys 364, 241 - 246.
48. Johnson GK and Organ CC (1997). Prostaglandin E2 and interleukin-1 concentrations in nicotine-exposed oral keratinocyte cultures. J Periodontal Res 32, 447 - 454.
49. Kondo M, Finkbeiner WE, and Widdicombe JH (1991). Simple technique for culture of highly differentiated cells from dog tracheal epithelium. Am J Physiol 261, L106 - L117.
50. Zabner J, Zeiher BG, Friedman E, and Welsh MJ (1996). Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol 70, 6994 - 7003.
51. Davis TL, Rabinovitz I, Futscher BW, Schnolzer M, Burger F, Liu Y, Kulesz-Martin M, and Cress AE (2001). Identification of a novel structural variant of the alpha 6 integrin. J Biol Chem 276, 26099 - 26106.
52. Litt MD, Simpson M, Recillas-Targa F, Prioleau MN, and Felsenfeld G (2001). Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J 20, 2224 - 2235.
53. Holliday R and Pugh JE (1975). DNA modification mechanisms and gene activity during development. Science 187, 226 - 232.
54. Riggs AD (2002). X chromosome inactivation, differentiation, DNA methylation revisited, with a tribute to Susumu Ohno. Cytogenet Genome Res 99, 17 - 24.
55. Riggs AD (1975). X inactivation, differentiation, DNA methylation. Cytogenet Cell Genet 14, 9 - 25.
56. Futscher BW, O'Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, Seftor RE, Hendrix MJ, and Domann FE (2002). Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 6, 380 - 389.
57. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, and Srivastava S (2000). p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275, 6051 - 6054.
58. Bridges D and Moorhead GB (2004). 14-3-3 Proteins: a number of functions for a numbered protein. Sci STKE 2004, re10.
59. Fu H, Subramanian RR, and Masters SC (2000). 14-3-3 Proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40, 617 - 647.